We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5
Read MoreHide Full Article
Varian Medical Systems recently announced the release of an FDA-approved treatment planning software — Eclipse 15.5. This will help clinicians treat with more accuracy and efficiency.
Eclipse 15.5 also provides treatment planning support for Varian's HyperArc Oncology Systems (HDRT) for efficient and automated delivery of complex stereotactic radiosurgery. HyperArc HDRT is a new type of radiosurgery treatment. Eclipse 15.5 offers Graphics Processing Unit (GPU) support to help physicians optimize and speedily calculate the dose.
Eclipse 15.5 features Multi-criteria optimization (MCO) which allows clinicians to explore the application of different clinical criteria. According to the company, According to the company, MCO focuses on finding the optimal plan faster for a given patient with minimal trial and error iterations.
In the last reported third quarter, Varian Medical’s revenues declined 1.9% at Oncology Systems. The company is consistently trying to turn around its Oncology Systems business.. Apart from the latest development, the company recently announced FDA clearance for its revolutionary Halcyon product. The company received orders from 10 countries for the system. In North America, the company signed an agreement with PetCure Oncology to bring an unprecedented level of care to pets suffering from cancer.
According to a report by Markets And Markets, the global oncology information system market is expected to reach a worth of $2.6 billion by 2019 at a CAGR of 8.5% from 2014 to 2019. Considering the huge potential of the market, we believe the latest development is a strategic fit.
Over the past three months, Varian Medical has outperformed the broader industry in terms of price. The company has returned 2.1%, comparing favorably with the sub-industry’s gain of 0.3%.
Estimate Revision Trend
The estimate revision trend has been favorable for the company. For the current year, two estimates moved north compared with one movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for the full year has increased from $3.92 to $3.96 per share over the same period.
Zacks Rank & Key Picks
Varian Medicalcarries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Amedisys, Inc. (AMED - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Amedisys and IDEXX carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 5.7% over the last year.
IDEXX has a long-term expected earnings growth rate of 19.8%. The stock has gained around 45% over the last year.
4 Promising Stock Picks to Keep an Eye On
With news stories about computer hacking and identity theft becoming increasingly commonplace, the cybersecurity industry looks like a promising investment opportunity. But which stocks should you buy? Zacks just released Cybersecurity: An Investor’s Guide to Locking Down Profits to help answer this question.
This new Special Report gives you the information you need to make well-informed investment choices in this space. More importantly, it also highlights 4 cybersecurity picks with strong profit potential.
Image: Bigstock
Varian Medical (VAR) Releases FDA-Approved Eclipse 15.5
Varian Medical Systems recently announced the release of an FDA-approved treatment planning software — Eclipse 15.5. This will help clinicians treat with more accuracy and efficiency.
Eclipse 15.5 also provides treatment planning support for Varian's HyperArc Oncology Systems (HDRT) for efficient and automated delivery of complex stereotactic radiosurgery. HyperArc HDRT is a new type of radiosurgery treatment. Eclipse 15.5 offers Graphics Processing Unit (GPU) support to help physicians optimize and speedily calculate the dose.
Eclipse 15.5 features Multi-criteria optimization (MCO) which allows clinicians to explore the application of different clinical criteria. According to the company, According to the company, MCO focuses on finding the optimal plan faster for a given patient with minimal trial and error iterations.
In the last reported third quarter, Varian Medical’s revenues declined 1.9% at Oncology Systems. The company is consistently trying to turn around its Oncology Systems business.. Apart from the latest development, the company recently announced FDA clearance for its revolutionary Halcyon product. The company received orders from 10 countries for the system. In North America, the company signed an agreement with PetCure Oncology to bring an unprecedented level of care to pets suffering from cancer.
According to a report by Markets And Markets, the global oncology information system market is expected to reach a worth of $2.6 billion by 2019 at a CAGR of 8.5% from 2014 to 2019. Considering the huge potential of the market, we believe the latest development is a strategic fit.
Over the past three months, Varian Medical has outperformed the broader industry in terms of price. The company has returned 2.1%, comparing favorably with the sub-industry’s gain of 0.3%.
Estimate Revision Trend
The estimate revision trend has been favorable for the company. For the current year, two estimates moved north compared with one movement in the opposite direction over the last two months. As a result, the Zacks Consensus Estimate for the full year has increased from $3.92 to $3.96 per share over the same period.
Zacks Rank & Key Picks
Varian Medicalcarries a Zacks Rank #3 (Hold). A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Amedisys, Inc. (AMED - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Amedisys and IDEXX carry a Zacks Rank #2 (Buy) each. You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Amedisys has a long-term expected earnings growth rate of 18.2%. The stock has gained 5.7% over the last year.
IDEXX has a long-term expected earnings growth rate of 19.8%. The stock has gained around 45% over the last year.
4 Promising Stock Picks to Keep an Eye On
With news stories about computer hacking and identity theft becoming increasingly commonplace, the cybersecurity industry looks like a promising investment opportunity. But which stocks should you buy? Zacks just released Cybersecurity: An Investor’s Guide to Locking Down Profits to help answer this question.
This new Special Report gives you the information you need to make well-informed investment choices in this space. More importantly, it also highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>